

Pulmonary hypertension in Switzerland: treatment and clinical course

Manuel Fischler^a, Rudolf Speich^a, Lorenz Dorschner^a, Laurent Nicod^b, Guido Domenighetti^c, Michael Tamm^d, Thierry Rochat^e, John-David Aubert^f, Silvia Ulrich^a for the Swiss Society for Pulmonary Hypertension

^a University Hospital, Zurich, Switzerland

^b University Hospital, Bern, Switzerland

^c Regional Hospital, Locarno, Switzerland

^d University Hospital, Basel, Switzerland

^e University Hospital, Geneva, Switzerland

^f University Hospital, Lausanne, Switzerland

Abstract

Background: The prognosis of pulmonary hypertension (PH), especially idiopathic pulmonary arterial hypertension (IPAH), has improved during the recent years. The Swiss Registry for PH represents the collaboration of the various centres in Switzerland dealing with PH and serves as an important tool in quality control. The objective of the study was to describe the treatment and clinical course of this orphan disease in Switzerland.

Methods: We analyzed data from 222 of 252 adult patients, who were included in the registry between January 1999 and December 2004 and suffered from either PAH, PH associated with lung diseases or chronic thromboembolic PH (CTEPH) with respect to the following data: NYHA class, six-minute walking distance (6-MWD), haemodynamics, treatments and survival.

Results: If compared with the calculated expected figures the one, two and three year mean survivals in IPAH increased from 67% to 89%, from 55% to 78% and from 46% to 73%, respectively. Most patients (90%) were on oral or inhaled therapy and only 10 patients necessitated lung transplantation. Even though pulmonary endarterectomy (PEA) was performed in only

7 patients during this time, the survival in our CTEPH cohort improved compared with literature data and seems to approach outcomes usually seen after PEA. The 6-MWD increased maximally by 52 m and 59 m in IPAH and CTEPH, respectively, but in the long term returned to or below baseline values, despite the increasing use of multiple specific drugs (overall in 51% of IPAH and 29% of CTEPH).

Conclusion: Our national registry data indicate that the overall survival of IPAH and presumably CTEPH seems to have improved in Switzerland. Although the 6-MWD improved transiently, it decreased in the long term despite specific and increasingly combined drug treatment. Our findings herewith underscore the progressive nature of the diseases and the need for further intense research in the field.

Key words: chronic thromboembolic pulmonary hypertension; endothelin receptor antagonists; bosentan; haemodynamics; idiopathic pulmonary arterial hypertension; New York Heart Association; phosphodiesterase-5 inhibitors; sildenafil; prostanoids; Ilomedin; pulmonary hypertension; registry; 6-minute walking distance; survival; treatment

Financial support: The Swiss Society for Pulmonary Hypertension received financial support from Actelion Switzerland to run the registry.

Abbreviations

CTEPH Chronic thromboembolic pulmonary hypertension

IPAH Idiopathic pulmonary artery hypertension

NYHA New York Heart Association

PAH Pulmonary arterial hypertension

PEA Pulmonary endarterectomy

PH Pulmonary hypertension

6-MWD 6-minute walking distance

SVO₂ Mixed venous oxygen saturation

Introduction

Pulmonary hypertension (PH) comprises a group of orphan diseases with a poor prognosis if untreated. The revised Venice classification [1] includes pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH) as the main classes that intrinsically afflict the pulmonary circulation thereby distinguishing them from PH due to left heart disorders or chronic hypoxaemia. PAH is histologically characterized by proliferation and myofibrotic remodelling of small pulmonary artery vessel walls and can be subdivided into idiopathic (IPAH) and familial PAH, such as PAH associated with other conditions (collagen vascular disease, congenital heart disease, portal hypertension, HIV infection, drug or substance abuse). CTEPH can affect the proximal or distal pulmonary arteries. Patients with a proximal CTEPH can be treated by pulmonary endarterectomy (PEA) [2]. This highly complex operation is performed only in a few centres worldwide and in Switzerland, it has only recently become available in collaboration with the German centre. However, CTEPH may share common vasoreactivity properties with PAH and hence be amenable to vasodilator treatment [3].

Before the availability of specific therapy, the median survival of IPAH was 2.8 years, with one and three year survival of 68% and 48% [4]. Based on these data from the US registry an equation including the pulmonary artery pressure, right atrial pressure and cardiac index was developed to predict survival (NIH formula).

Since the introduction of intravenous epoprostenol in 1995, the 1 and 3 year survival rates have increased to 88% and 68%, respectively [5]. Epoprostenol treatment, however, was limited by the necessity of continuous intravenous infusion through a central venous line prone to various complications and therefore has rarely been used in Switzerland [6]. Advances in diagnosis and new therapeutic options including inhaled iloprost [7], oral bosentan [8] and sildenafil [9] have created an increased interest in PH. The first report from the Swiss Registry on patients with PH in Switzerland dates from 2001 [6]. In this article we present an update on treatment, clinical course and survival of patients with PH in Switzerland.

Material and methods


The Swiss PH Registry was opened in 1999 and includes prospective patient data from nine Swiss Hospitals (all five university hospitals and four cantonal hospitals). All patients provide written informed consent. PH is defined as a mean pulmonary artery pressure (mPAP) of >25 mm Hg at rest or >30 mm Hg at exercise, and a pulmonary arterial occlusion pressure >15 mm Hg [10]. According to the current clinical classification [1] patients are grouped in the following classes: 1. PAH 2. PH due to left heart disease 3. PH associated with chronic lung disease, 4. CTEPH, 5. PH due to miscellaneous disorders. The following data were collected: age, gender, diagnosis according to the clinical classification [1], date of PH diagnosis, height, weight, blood pressure, heart rate and

oxygen saturation at rest, NYHA class, six-minute walking distance (6-MWD), haemodynamics assessed by right heart catheterization: (mPAP), cardiac output (CO), right atrial pressure (RAP), mixed venous oxygen saturation (SvO_2), current medication and survival.

For the present paper, we analyzed data from 252 adult patients (>18 years of age) who were included in the registry between January 1999 and December 2004. Of these, 30 patients were excluded for the following reasons: (1.) patients with PH due to left heart disease (as this registry focuses on precapillary PH, $n = 2$), (2.) patients with various rare medical conditions (class 5) ($n = 9$), and (3.) patients without follow-up data ($n = 19$). Thus, overall data from 222 patients were available for analysis (figure 1). Data collection included patients providing data at the following three time points: 1. the first visit of the patient (baseline = BL), 2. the visit at the time of the best 6-MWD (best), as the 6-MWD is used as the primary end-point in most clinical trials in PH and we hoped to obtain some information about the maximal achievable improvement under therapy, and at the last visit (last). Patients' survival was completed at the time of death, or censored at the time of the last observation, pulmonary endarterectomy (PEA) or transplantation. We compared survival observed in the subset of 76 IPAH patients with the expected survival calculated for each patient based on the NIH formula [4]. This US national prospective trial with 194 patients with idiopathic PH estimates from a proportional hazards model, an equation to predict a patient's chance of survival. This NIH formula is calculated as follows: $P(t) = [H(t)]^{A(x,y,z)}$, where $A(x,y,z) = \text{EXP}(0.007325x + 0.0526y - 0.3235z)$, x is mean pulmonary artery pressure, y is mean right atrial pressure, and z is cardiac index. The probabilities of survival at 1, 2,

Figure 1

Enrolment and Disposition of Subjects. PAH: Pulmonary arterial hypertension, WHO-Venice class V: Pulmonary hypertension caused by disorders directly affecting the pulmonary vasculature, CTEPH: Chronic thromboembolic pulmonary hypertension.



and 3 years are given by the following: P(1) = 0.75^A; P(2) = 0.65^A; and P(3) = 0.55^A.

All results are expressed as means (standard deviations). Statistical analysis was performed using SPSS version 12.0.1 software package. The paired T-test was used

for continuous variables and the Chi square test for discrete variables. Kaplan-Meier statistics was used to estimate overall survival. A p value <0.05 was considered to be significant.

Results

The baseline characteristics of the 222 patients included in the current analysis are shown in table 1. The mean follow-up was 24 (17) months (range 1-70). The time between the baseline and the best values was 12 (13) months, and

the time between best and last values 12 (13) months. Mean age was 57 (16) years and 60% of the patients were female. The mPAP was not significantly different in patients with IPAH and those with CTEPH [51 (18) respectively 46 (13)

Figure 2

Kaplan-Meier estimates of survival in patients with PH in Switzerland. There was no significant difference in survival of the main three WHO groups included in the current analysis. Compared with IPAH, patients suffering from PAH associated with collagen vascular diseases (CVD) and HIV disease had a significantly worse survival (p = 0.034 and p = 0.027, respectively). IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, CVD: Collagen vascular disease, Lung: Pulmonary Hypertension associated with lung diseases and/or hypoxaemia.




Table 1


Baseline characteristics of the whole patient population (n = 222).

	All patients (n = 222)	IPAH (n = 76)	CTEPH (n = 66)	CVD (n = 33)	HIV (n = 10)	Lung (n = 17)	Others (n = 20)
Age in years (SD)	57 (16)	55 (17)	63 (13)	57 (15)	44 (13)	63 (11)	48 (19)
Female sex (n)	134 (60%)	52 (68%)	37 (56%)	23 (70%)	4 (40%)	6 (35%)	12 (60%)
Body mass index in kg/m ² (SD)	26 (7)	27 (8)	26 (5)	24 (5)	21 (3)	26 (4)	26 (7)
NYHA functional class (n)							
- Class I	1 (0.5%)			1 (3%)			
- Class II	24 (11%)	7 (8%)	9 (14%)	3 (9%)		2 (12%)	2 (10%)
- Class III	144 (65%)	53 (71%)	40 (61%)	20 (61%)	1 (10%)	8 (47%)	15 (75%)
- Class IV	53 (23%)	16 (21%)	17 (25%)	9 (27%)	9 (90%)	7 (41%)	3 (15%)
6-MWD in m (SD)	356 (142)	353 (139)	364 (146)	359 (157)	395 (109)	311 (146)	351 (139)
mPAP in mm Hg (SD)	49 (17)	51 (19)	46 (13)	44 (13)	48 (10)	47 (15)	64 (23)
RAP in mm Hg (SD)	9 (7)	10 (8)	10 (6)	7 (5)	6 (4)	7 (4)	11 (7)
CO in L/min (SD)	4.1 (1.3)	4.2 (1.3)	3.7 (1.0)	4.0 (1.1)	3.9 (1.2)	4.5 (1.0)	5.1 (2.0)
SVO ₂ in % (SD)	59 (11)	61 (10)	58 (7)	58 (16)	59 (6)	55 (18)	64 (8)

IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, CVD: Collagen vascular disease, HIV: Human immunodeficiency virus infection, Lung: Pulmonary Hypertension associated with lung diseases and/or hypoxemia, Others: Other causes of pulmonary artery hypertension, NYHA: New York Heart Association, 6-MWD: 6-minute walking distance, mPAP: mean pulmonary artery pressure, RAP: mean right atrial pressure, CO: mean cardiac output, SVO₂: mixed venous oxygen saturation
Data are given as means, standard deviation (SD) and percentages (%)

Figure 3

Kaplan-Meier estimates of survival in patients with IPAH in Switzerland compared with the expected survival according to the NIH formula [4] and literature data [5, 12]. IPAH: Idiopathic pulmonary artery hypertension.



mm Hg; $p = 0.16$). During the observation period, 147 patients survived, 10 underwent lung transplantation, 7 PEA and 58 died. The 1, 2, 3 and 5 year survival of the whole population was 85%, 74%, 71%, and 53%, respectively. There was no difference in survival between patients with PAH, CTEPH or patients with lung diseases (figure 2). Compared with IPAH, patients suffering from PAH associated with connective tissue diseases and HIV had a significantly worse survival ($p = 0.034$ and $p = 0.027$, respectively).

When compared to the expected survival calculated according to the NIH formula, the 1, 2, and 3 year mean survival for patients with IPAH increased from 67% to 89%, from 55% to 78% and from 46% to 73% and was comparable with

other investigated cohorts (figure 3) [5, 12]. For further analysis concerning treatment, only the major patient groups IPAH ($n = 76$) and CTEPH ($n = 66$) were included. At baseline, most patients were in NYHA class III (65%) and IV (24%) with no difference between the two groups. Follow-up data of patient allocation to NYHA classes are shown in table 2. Initially, medical care seemed effective, a significant improvement from baseline to best with more IPAH patient being in NYHA class I or II compared to III was found ($p = 0.025$). In the long term, patients seemed to either respond or not respond to therapy, as the number of NYHA class III patients decreased significantly from baseline to the last visit at the expense of class II (therapy-responders) and class IV (non-responders). There was a similar trend in CTEPH, although it seemed that the percentage of non-responders was somewhat higher in this group (table 2).

Therapy seemed also to be effective initially as regards exercise capacity measured by the 6-MWD, which significantly increased from baseline to best in both IPAH and CTEPH ($p < 0.001$ for both groups, figure 4). However, this considerable improvement could not be maintained in the long-term as the 6-MWD declined to baseline values in both groups ($p > 0.001$ between best and last, $p = ns$ between baseline and last for all groups, figure 4).

Treatments are divided into basic (oxygen, diuretics, oral anticoagulation) and PH-specific (prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors) as well as into

Figure 4

Changes in 6-MWD over time in patients with IPAH ($n = 59$) and CTEPH ($n = 45$), in whom data at all three time points were available. The difference between baseline and best as well as between best and last, respectively, was significant at the same P values for both IPAH and CTEPH ($P < 0.001$ for all comparisons). IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, 6-MWD: 6-minute walking distance.




Table 2

Percentages of NYHA functional classes in patients with IPAH ($n = 65$) and CTEPH ($n = 50$), in whom data at all three time points were available.

	Baseline		Best		Last	
	IPAH	CTEPH	IPAH	CTEPH	IPAH	CTEPH
NYHA I (%)	0	0	1	6	4	4
NYHA 2 (%)	8	14	23	20	19	14
NYHA 3 (%)	69	60	48	40	37	44
NYHA 4 (%)	23	26	28	34	40	38

IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, NYHA: New York Heart Association

uretics, oral anticoagulation) and PH-specific (prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors) as well as into single (only one specific drug) and multiple (more than one specific drug) medications.

The basic treatment at all time points is shown in table 3. Basic therapy was broadly applied in all groups. At the last visit 40% of all patients (IPAH + CTEPH) were on oxygen, 54% on diuretics and 87% on oral anticoagulation, with no major differences between the groups. In the CTEPH group all but one (haemophilia patient, 65/66) were receiving oral anticoagulation at their last visit. From baseline to the time of the best 6-MWD there were marked increases in the use of oxygen, diuretics and oral anticoagulation in all groups.

The percentage of patients receiving specific therapy significantly increased from baseline to the last visit; from 31% to 89% in patients with

IPAH and from 31% to 81% in CTEPH. The overall number of patients receiving each of the five specific treatment modalities including multiple therapies is shown in table 4.

Regarding the drugs used for single specific therapy, there was a tendency towards a decreased use of inhaled iloprost over time in both group and a tendency towards an increased use of bosentan in CTEPH patients.

From baseline to best, respectively last visit, there was a steady increase in the use of multiple specific drugs (from 4% to 29% respectively 51% in IPAH patients, and from 4% to 16% respectively 29% in CTEPH patients). Considering the various combination treatments (table 4), the most frequently applied combination in IPAH was inhaled iloprost with bosentan and in CTEPH inhaled iloprost with sildenafil. More than a quarter of the IPAH patients were on three or more drugs at the last visit.

Discussion

The present study summarizes the therapeutic management and clinical course of PH patients from the Swiss registry. The overall survival in the present PH cohort was 71% at three and 53% at five years. Whereas survival of patients with IPAH and CTEPH as well as those with PH associated

with lung diseases was comparable, prognosis of PAH associated with connective tissue diseases and HIV infection was significantly worse. This is in line with the previously published cohorts. In a recent series of 91 patients receiving continuous intravenous epoprostenol treatment, the 3-year

Table 3
Basic treatments at the three time points.

	Oxygen (%)		Diuretics (%)		OAK (%)	
	IPAH	CTEPH	IPAH	CTEPH	IPAH	CTEPH
Baseline	25	22	33	36	59	79
Best	41*	30	43	55*	84**	89
Last	42	38	49	61	84	98

IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, OAK = oral anticoagulation. *p <0.05; **p <0.001

Table 4
Single and multiple specific drug therapy (percentages) at the three time points in IPAH and CTEPH patients.

	IPAH			CTEPH		
	BL	Best	Last	BL	Best	Last
Specific Therapy*	26 of 83 (31%)	63 of 75 (84%)	67 of 75 (89%)	22 of 70 (31%)	44 of 60 (73%)	46 of 57 (81%)
Single drug						
CCB (%)	8	2	0	9	5	4
Ilo inh (%)	50	22	16	71	51	30
Ilo iv (%)	8	6	5	4	0	2
Bos (%)	30	37	25	15	23	26
Sil (%)	0	4	3	0	5	9
Multiple drugs						
Bos+Sil (%)	0	2	5	4	2	7
Bos+Ilo (%)	4	19	16	0	7	7
Ilo+Sil (%)	0	2	3	0	5	13
3 and > (%)	0	6	27	0	2	2

IPAH: Idiopathic pulmonary artery hypertension, CTEPH: Chronic thromboembolic pulmonary hypertension, BL = Baseline, CCB: Calcium Channel Blocker, Ilo inh: Ilomedin inhalation, Ilo iv: Ilomedin intravenous, Bos: Bosentan, Sil: Sildenafil, * Overall number of patients on specific drug therapy

survival was 65% in IPAH patients compared with only 34% in patients with PAH associated with connective tissue diseases [14] thus confirming earlier data showing the dismal prognosis of these patients [15]. Data from the Swiss HIV Cohort showed lower survival of patients with mostly untreated HIV-related PAH (median 1.3 years) compared with matched HIV-infected patients without PAH (median 2.6 years) [16]. Similarly, a recent series of 82 patients with HIV-related PAH receiving treatment with intravenous epoprostenol (24%) and/or combination anti-retroviral therapy (48%) confirmed a poor 3 year survival (47%) [17]. Regarding only those IPAH patients for whom the most survival data are available, the one year survival in our cohort was 89%, which is similar to the one year survival found in the French national registry [18]. However, our IPAH 3 year survival rate of 73% is much better than the expected figure (46%) calculated using the PH-survival formula including various haemodynamic parameters based on a historical NIH cohort [4]. Although a certain improvement in survival compared with historical cohorts can be expected due to advances in general patient care and ameliorated living circumstances, the magnitude seen here suggests an effect of PH specific therapy. Remarkably, only 10 patients in the present cohort needed lung transplantation. This is even more surprising considering the fact that only seven patients in our series were receiving continuous intravenous prostaglandin treatment and that the prognosis was nonetheless comparable with recently described similar cohorts [5, 12]. This might suggest that modern oral or inhaled specific treatment options, including combination therapies, may be as effective as intravenous prostaglandins alone [19–22] whilst avoiding the complications frequently associated with intravenous lines and pump systems. The effectiveness of specific non-invasive combination therapies may be the reason why only a minority of the NYHA IV patients in our cohort received intravenous iloprost, despite international recommendations [23]. In addition, this may be especially true for patient groups with a previously unfavourable prognosis such as HIV, since a recent open label trial in 16 HIV patients demonstrated an improvement in exercise capacity, haemodynamics and quality of life with no deaths after 3 months of bosentan therapy [24].

Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with PH [25] but there are no data showing that long-term supplemental oxygen is beneficial in pulmonary hypertension with or without hypoxaemia. At the last time point 42% of our IPAH patients were on oxygen therapy. This is rather a high number compared with Breathe-1 (33%) and STRIDE-1 (30%). There may be an overuse in Switzerland and this must be better monitored. Available data on drug treatment based on pulmonary hypertension registries are very limited.

In an Israeli study on IPAH patients most were on anticoagulation at the first registration (95% vs. 59% in our study) but only 13% were already treated with prostacyclins (compared with 20% in our study) [26]. At baseline, 31% of the IPAH patients were on specific drug medication (20% on prostaglandins and 9% on bosentan). These data differ from a large American cohort on patients with PAH, where 31% of patients were on calcium channel blockers at the time of referral and only a small number on prostaglandins (2.4%) or bosentan (3.1%) [27].

Our favourable survival data might be explained by the introduction of specific vasodilator combination therapy. As shown in figure 4, after one year of treatment the 6-MWD improved by 52m and 59m in IPAH and CTEPH, respectively. These figures are comparable to those reported in the recent large randomized trials [7–9, 28]. After another year, however, the 6-MWD had decreased to the baseline levels, emphasizing the fact that these disorders exhibit a relentlessly progressive nature. At this time point more than half of the IPAH patients and almost one third of those with CTEPH were on combination therapy, predominantly inhaled iloprost and bosentan in IPAH, and inhaled iloprost and sildenafil in CTEPH of patients. So far, there are numerous case series of mainly PAH patients demonstrating a potential benefit of vasodilator combination therapy [29–33]. After the first randomized trial of bosentan added on to intravenous epoprostenol failed to show a benefit [34], probably due to the insufficient number of patients included, a recent randomized study on the addition of inhaled iloprost to bosentan revealed a significant improvement in the 6-MWD, a decrease in NYHA functional class and a delayed time to clinical worsening in the treatment group [35].

Until recently it was thought that CTEPH has a better prognosis than IPAH. Kunieda et al. compared 48 untreated CTEPH-patients with 32 untreated IPAH-patients and found a survival of 73% and 43% at 3 years, respectively, and 44% and 23% at 6 years, respectively [36]. CTEPH patients are believed to respond poorly to vasodilator therapy attributed to a more fixed vessel obstruction by clots and reactive fibrotic remodelling of the more proximal pulmonary artery vessel wall. On the other hand, the course of the development of CTEPH possibly differs from other PH-forms. Furthermore CTEPH is the only potentially curable PH-form. The observation of an almost super imposable survival curve of CTEPH and IPAH patients in the current series might be surprising. It is, however, well known that CTEPH may show microvascular changes comparable to IPAH, including plexiform lesions [37]. In addition, a recent study has shown that CTEPH and IPAH may share vasoreactive properties [3]. Remarkably, the survival of our CTEPH cohort (from which only seven underwent PEA) was only slightly lower than that of

the 532 patients who underwent PEA at the world's largest centre in San Diego [38].

The present study based on national registry data has a number of limitations. As noted in the methods section one of our chosen time point is the "best 6-MWD". This is somewhat arbitrary and might favour statistically significant results between this point and BL or the last visit. However, it was our intention to gain insight into the maximal possible therapeutic effect. Therefore we choose the 6-MWD as the most widely used endpoint of clinical trials. This enables us to compare our registry data, which are likely to represent ordinary clinical practice, with the results of randomized controlled trials in the field. The selection of the time of the best 6-MWD as a further data point also provided us with an additional and more complete data set. This would not have been the case if we had chosen another fixed time point (e.g. one year after therapy). Although prospectively entered, registry data collection is not scheduled prospectively as in proper clinical trials but reflects every day clinical practice where patients are scheduled based on the well being, illness, social and occupational availability of both patients and health care providers. Therefore, registry data might be flawed by missing or inconstant parameters. In comparison with clinical trials, every patient with the disease can be entered in the registry regardless of co-morbidities. However registry entering is voluntary and therefore some PH-patients might be unidentified. Summarizing the drawbacks and advantages, we believe that nation wide registry data including a

broad patient collective (presumably also multi- or comorbid patients, who would never be entered in a randomized study) provide important information for health care providers in the field.

In conclusion, these data retrieved from the Swiss PH Registry describe the management of patients with PH in Switzerland with emphasis on the major groups IPAH and CTEPH. They indicate an improvement in prognosis of these patients in the recent years, including a low percentage of patients necessitating intravenous prostaglandin therapy or lung transplantation. Interestingly, patients with CTEPH exhibited a similar improvement in prognosis under standard vasodilator therapy. Our findings encourage the thorough maintenance and complementation of the Swiss PH registry in order to acquire high quality surveillance data of PH patient care in the future.

The authors are indebted to Ulla Treder, R.N. for her continuing efforts in maintaining the high data quality of the registry, Actelion, Baden, Switzerland, for their financial and technical support, and Helena Boeschstein for proof reading the manuscript.

Correspondence:

Dr. med. Manuel Fischler
Department of Internal Medicine
Raemistrasse 100
CH-8091 Zurich
Switzerland
manuel.fischler@usz.ch

References

- Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol.* 2004;43:5S-12S.
- Mayer E. Surgical treatment of chronic thromboembolic pulmonary hypertension. *Swiss Med Wkly.* 2006;136:491-7.
- Ulrich S, Fischler M, Speich R, Popov V, Maggiorini M. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. *CHEST.* 2006;130:841-6.
- D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. *Ann Intern Med.* 1991;115:343-55.
- McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation.* 2002;106:1477-82.
- Stricker H, Domenighetti G, Popov W, Speich R, Nicod L, Aubert JD, et al. Severe pulmonary hypertension: data from the Swiss Registry. *Swiss Med Wkly.* 2001;131:346-50.
- Olschewski H, Simonneau G, Galie N, Higgenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med.* 2002;347:322-9.
- Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med.* 2002;346:896-903.
- Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. *N Engl J Med.* 2005;353:2148-57.
- Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol.* 2004;43:40S-7S.
- Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. *Am J Respir Crit Care Med.* 2000;161:487-92.
- Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *J Am Coll Cardiol.* 2002;40:780-8.
- Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation.* 1984;70:580-7.
- Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. *Am J Respir Crit Care Med.* 2003;167:580-6.
- Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. *Br J Rheumatol.* 1996;35:989-93.
- Opravil M, Pechère M, Speich R, Joller HI, Jenni R, Russi EW, et al. HIV-associated primary pulmonary hypertension: a case control study. *Swiss HIV Cohort Study.* *Am J Respir Crit Care Med.* 1997;155:990-5.
- Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med.* 2003;167:1433-9.
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary Arterial Hypertension in France. Results from a national Registry. *Am J Respir Crit Care Med.* 2006;173:1023-30.

- 19 Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. *Eur Heart J*. 2005;26:1895–902.
- 20 McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J*. 2005;25:244–9.
- 21 Corris P, Burgess G, Parpia T, Barst R. Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH). *Eur Respir J*. 2005;26:475s.
- 22 Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galie N, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. *Thorax*. 2005;60:981–3.
- 23 Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative Analysis of Clinical Trials and Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. *J Am Coll Cardiol*. 2004;43:81S–8S.
- 24 Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2004;170:1212–7.
- 25 Roberts DH, Lepore JJ, Maroo A, Semigran MJ, Ginns LC. *CHEST*. 2001;120:1547–55.
- 26 Appelbaum L, Yigla M, Bendayan D, Reichart N, Fink G, Priel I, et al. Primary Pulmonary Hypertension in Israel. A National Survey. *CHEST*. 2001;119:1801–6.
- 27 Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A united states-based registry for pulmonary arterial hypertension: 1982–2006. *Eur Respir J Express*. 2007; September 5.
- 28 Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*. 2002;165:800–4.
- 29 Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. *Swiss Med Wkly*. 2006;136:114–8.
- 30 Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *J Am Coll Cardiol*. 2003;42:158–64.
- 31 Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2004;24:1007–10.
- 32 Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. *Eur Respir J*. 2005;26:858–63.
- 33 Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. *Eur Respir J*. 2006;28:691–4.
- 34 Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J*. 2004;24:353–9.
- 35 McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2006;174:1257–63.
- 36 Kunieda T, Nakanishi N, Satoh T, Kyotani S, Okano Y, Nagaya N. Prognoses of primary pulmonary hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. *Intern Med*. 1999;38:543–6.
- 37 Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. *CHEST*. 1993;103:685–92.
- 38 Archibald CJ, Auger WR, Fedullo PF, Channick RN, Kerr KM, Jamieson SW, et al. Long-term outcome after pulmonary thromboendarterectomy. *Am J Respir Crit Care Med*. 1999;160:523–8.

SMW

Established in 1871
Formerly: Schweizerische Medizinische Wochenschrift
Swiss Medical Weekly

The European Journal of Medical Sciences

The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW's impact factor has been steadily rising. The 2006 impact factor is 1.346.
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website <http://www.smw.ch> (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of professional statisticians for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing

Editorial Board

Prof. Jean-Michel Dayer, Geneva
Prof Paul Erne, Lucerne
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(editor in chief)
Prof. Werner Straub, Berne (senior editor)
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee

Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:

http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: <http://www.smw.ch>